Nuo Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

Nuo Therapeutics, Inc.

Consolidated Statements of Changes in Stockholders' Equity (Deficit)

For the Years Ended December 31, 2025 and 2024

Common Stock
	Shares	Amount (par $0.0001)	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
Balance, December 31, 2023	44,241,516	$4,424	$30,970,965	$(29,936,241)	$1,039,148
Stock-based compensation expense	-	-	56,652	-	56,652
Issuance of common stock for cash proceeds	2,000,000	200	1,499,800	-	1,500,000
Issuance of common stock for warrant exercise	270,000	27	151,173	-	151,200
Issuance of common stock for cashless warrant exercise	86,889	9	(9)	-	-
Issuance of common stock for option exercise	217,709	22	90,395	-	90,417
Net loss	-	-	-	(2,323,705)	(2,323,705)
Balance, December 31, 2024	46,816,114	$4,682	$32,768,976	$(32,259,946)	$513,712
Stock-based compensation expense	-	-	85,986	-	85,986
Issuance of common stock for cash proceeds	527,612	53	791,365	-	791,418
Issuance of common stock for option exercises	283,853	28	113,513	-	113,541
Issuance of common stock for cashless option exercises	520,844	52	(52)	-	-
Issuance of common stock for services rendered	30,616	3	50,997	-	51,000
Net loss	-	-	-	(2,512,216)	(2,512,216)
Balance, December 31, 2025	48,179,039	$4,818	$33,810,785	$(34,772,162)	$(956,559)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.